SkinBioTherapeutics plc (LON:SBTX – Get Free Report) rose 8.4% on Monday . The company traded as high as GBX 20.99 ($0.27) and last traded at GBX 20.98 ($0.27). Approximately 593,090 shares were traded during mid-day trading, a decline of 5% from the average daily volume of 625,984 shares. The stock had previously closed at GBX 19.36 ($0.25).
SkinBioTherapeutics Stock Performance
The company has a quick ratio of 10.01, a current ratio of 0.93 and a debt-to-equity ratio of 27.57. The stock has a market cap of £47.93 million, a P/E ratio of -12.90 and a beta of 2.01. The business has a 50 day moving average price of GBX 18.24 and a two-hundred day moving average price of GBX 15.61.
About SkinBioTherapeutics
SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis.
See Also
- Five stocks we like better than SkinBioTherapeutics
- The Risks of Owning Bonds
- How to Protect Your Portfolio When Inflation Is Rising
- P/E Ratio Calculation: How to Assess Stocks
- 3 Tech Stocks Defying Sector Weakness and Thriving in 2025
- Ride Out The Recession With These Dividend Kings
- Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Receive News & Ratings for SkinBioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SkinBioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
